中文

Untranslated

English
Chinese
French
German
Portuguese
Spanish
Russian
Japanese
Korean
Arabic
Irish
Greek
Turkish
Italian
Danish
Romanian
Indonesian
Czech
Afrikaans
Swedish
Polish
Basque
Catalan
Esperanto
Hindi
Lao
Albanian
Amharic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Bulgarian
Cebuano
Chichewa
Corsican
Croatian
Dutch
Estonian
Filipino
Finnish
Frisian
Galician
Georgian
Gujarati
Haitian
Hausa
Hawaiian
Hebrew
Hmong
Hungarian
Icelandic
Igbo
Javanese
Kannada
Kazakh
Khmer
Kurdish
Kyrgyz
Latin
Latvian
Lithuanian
Luxembou..
Macedonian
Malagasy
Malay
Malayalam
Maltese
Maori
Marathi
Mongolian
Burmese
Nepali
Norwegian
Pashto
Persian
Punjabi
Serbian
Sesotho
Sinhala
Slovak
Slovenian
Somali
Samoan
Scots Gaelic
Shona
Sindhi
Sundanese
Swahili
Tajik
Tamil
Telugu
Thai
Ukrainian
Urdu
Uzbek
Vietnamese
Welsh
Xhosa
Yiddish
Yoruba
Zulu
Kinyarwanda
Tatar
Oriya
Turkmen
Uyghur

More Language

86-2164556180

cpd-service@caerulumpharma.com

Home
De Us
Products
Solutions
Resources
- Downloadable
- Imago gallery
FAQs
Contact Us

Home
Products
Bioactive moleculis
alii
AHR

Categories Products

Antineoplastic
- ACC
- Adenosine A2A
- ALK
- Androgen receptor inhibitor
- Apoptosis incitamentum
- ATR
- AXL
- BCl2-BH4
- Bcr-Abl
- BRAF
- BTK
- CDK
- Chk1
- CYP17
- DNA alkylating agente
- EED
- EGFR
- EP4
- ER
- FAK
- FGFR
- FLT3
- Glutaminase
- IDO
- IRA
- LOCULUS
- LXR
- MDM2
- MEK
- MET
- Nrf2
- P90RSK
- P97
- PAKS
- PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Hypoglycemic medicinae
- DPP-4
- SGLT-1
- SGLT-2
alii
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAC
- FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- mACHRs
- NF-κB
- NRTI
- PPAR
- RIP1
- S1PR
- SGC
- SYK
- α2δ-1
- αIIbβ3
- β2-adrenoceptor
- σ1

AHR

CAT #	Product Name	Descriptio
CPD3504	BAV-218

Contact Us

N. 401, 4th Solum, Aedificium 6, Quwu Road DLXXXIX, Minhang District, 200241 Shanghai, China
86-2164556180
In Sinis:
sales-cpd@caerulumpharma.com
International:
cpd-service@caerulumpharma.com

Inquisitionis

Percontationes de fructibus nostris, quaeso, electronicam tuam nobiscum relinque et intra 24 horas continuabimus.Inquisitionis

Tardus News

AstraZeneca moderantibus boost pro oncology medicinae accipit

AstraZeneca regulatory suscipit boost pro...

AstraZeneca duplicem boostem pro sua oncologia portfolio accepit die Martis, postquam US et moderatores Europaei subiectiones moderantes pro suis medicamentis acceperunt, primus gradus ad haec medicamenta approbavit. ...

Top VII Trends in pharmaceutical Research I...

Cum semper ingravescentibus pressionibus certare in ambitu oeconomico et technologico, societatibus pharmaceuticis et biotechicis, semper innovare debent in R&D programmatis suis ut antecedant ...

ARS-1620.

Secundum studium editum in Cell, investigatores inhibitorem specificum pro KRASG12C ARS-1602 elaboraverunt quod regressionem tumoris in muribus induxerunt. "Hoc studium vivo testimonio praebet quod mutant KRAS potest esse...

AstraZeneca regulatory suscipit boost pro...

AstraZeneca duplicem boostem pro sua oncologia portfolio accepit die Martis, postquam US et moderatores Europaei subiectiones moderantes pro suis medicamentis acceperunt, primus gradus ad haec medicamenta approbavit. ...

Top VII Trends in pharmaceutical Research I...

Cum semper ingravescentibus pressionibus certare in ambitu oeconomico et technologico, societatibus pharmaceuticis et biotechicis, semper innovare debent in R&D programmatis suis ut antecedant ...

FAQs
Downloadable
Contact Us

Mittere Email

QR code

x

Whatsapp Online Chat!

TOP

Close

Previous Next

Previous Maximize